ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease

Inclusion Criteria: * Men and women, between 18 and 80 years, inclusive. * Patients who are able and willing to give consent and able to attend all study visits. * Able to communicate sensations during the ExAblate MRgFUS treatment * Stable doses of all medications for 30 days prior to study entry and for the duration of the study. * Inclusion and exclusion criteria have been agreed upon by two members of the medical team. Exclusion Criteria: * Patients with unstable cardiac status including: * Unstable angina pectoris on medication * Patients with documented myocardial infarction within six months of protocol entry * Congestive heart failure requiring medication (other than diuretic) * Patients on anti-arrhythmic drugs * Severe hypertension (diastolic BP \> 100 on medication) * Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc. * Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease * Severely impaired renal function (estimated glomerular filtration rate \< 30ml/min/1.73 m2) or receiving dialysis * History of abnormal bleeding and/or coagulopathy * Cerebrovascular disease (multiple CVA or CVA within 6 months) * Symptoms and signs of increased intracranial pressure (e.g. headache, nausea, vomiting, lethargy, and papilledema) * Active or suspected acute or chronic uncontrolled infection * History …